Skip to main content
Clinical Trials/NCT02258360
NCT02258360UnknownNot Applicable

The Effect of Therapeutic Hypothermia After Cardiac Arrest on the Haemostasis.

University of Aarhus2 sites in 1 country82 target enrollmentStarted: February 2013Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
82
Locations
2
Primary Endpoint
Clotting time in seconds, EXTEM

Study Overview

Brief Summary

This is a sub-study to the Time-differentiated Therapeutic Hypothermia (TTH48, ClinicalTrials.gov Identifier: NCT01689077). TTH48 compares 24 with 48 hours of therapeutic hypothermia at a target temperature of 32-34°C in survivors of out-of-hospital cardiac arrest.

The overall aim of this sub-study is to examine the hemostasis in patients resuscitated after cardiac arrest and treated with 24 and 48 hours of therapeutic hypothermia

Our specific aims are:

  • To investigate the whole blood coagulation using the rotational thromboelastometry.
  • To investigate the function of platelets

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Out of hospital cardiac arrest of presumed cardiac cause
  • Return of spontaneous circulation (ROSC)
  • Glasgow Coma Score < 8
  • Age > 18 years and < 80 years

Exclusion Criteria

  • > 60 minutes from the circulatory collapse to ROSC
  • Time interval > 4 hours from cardiac arrest to initiation of therapeutic hypothermia
  • Terminal illness
  • Coagulation disorder
  • Unwitnessed asystolia
  • Cerebral performance category 3-4 before the cardiac arrest
  • Severe persistent cardiogenic shock
  • Pregnancy
  • Persistent cardiogenic shock (systolic blood pressure < 80 despite inotropic treatment)
  • New apoplexy or intracerebral hemorrhage
  • Lack of consent from the relatives
  • Lack of consent from the GP
  • Lack of consent from the patient if he/she wakes up and is relevant

Outcomes

Primary Outcomes

Clotting time in seconds, EXTEM

Time Frame: After 46 hours

Measured by thomboelastometry on the ROTEM®

Area under the curve, COL-test

Time Frame: After 46 hours

Platelet function will be measured using Multiplate®

Secondary Outcomes

  • Clot formation time in seconds, -EXTEM, INTEM, FIBTEM and HEPTEM(After 22 hours, 46 hours and 70 hours)
  • Maximum clot firmness (mm), -EXTEM, INTEM, FIBTEM and HEPTEM(After 22 hours, 46 hours and 70 hours)
  • Area under the curve, COL-test(After 22 hours and 70 hours)
  • Clotting time in seconds, EXTEM(After 22 hours and 70 hours)
  • Clotting time in seconds, -INTEM, FIBTEM and HEPTEM(After 22 hours, 46 hours and 70 hours)
  • Maximum velocity (mm/min), -EXTEM, INTEM, FIBTEM and HEPTEM(After 22 hours, 46 hours and 70 hours)
  • Area under the curve,- ADP, ASPI and TRAP-test.(After 22 hours, 46 hours and 70 hours)
  • Time to maximum velocity (s), -EXTEM, INTEM, FIBTEM and HEPTEM(After 22 hours, 46 hours and 70 hours)
  • Area under the curve, Clot stability test(After 22 hours, 46 hours and 70 hours)
  • Area under the curve, Thrombin generation(After 22 hours, 46 hours and 70 hours)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials